- Home
- EVG vs ABOS Comparison
EVG vs ABOS Comparison
Compare EVG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVG
- ABOS
- Stock Information
- Founded
- EVG 2005
- ABOS 1996
- Country
- EVG United States
- ABOS United States
- Employees
- EVG N/A
- ABOS N/A
- Industry
- EVG Investment Managers
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- EVG Finance
- ABOS Health Care
- Exchange
- EVG Nasdaq
- ABOS Nasdaq
- Market Cap
- EVG 149.5M
- ABOS 171.8M
- IPO Year
- EVG N/A
- ABOS 2021
- Fundamental
- Price
- EVG $11.04
- ABOS $2.40
- Analyst Decision
- EVG
- ABOS Strong Buy
- Analyst Count
- EVG 0
- ABOS 4
- Target Price
- EVG N/A
- ABOS $9.00
- AVG Volume (30 Days)
- EVG 49.4K
- ABOS 207.8K
- Earning Date
- EVG 01-01-0001
- ABOS 11-12-2024
- Dividend Yield
- EVG 8.68%
- ABOS N/A
- EPS Growth
- EVG N/A
- ABOS N/A
- EPS
- EVG N/A
- ABOS N/A
- Revenue
- EVG N/A
- ABOS N/A
- Revenue This Year
- EVG N/A
- ABOS N/A
- Revenue Next Year
- EVG N/A
- ABOS N/A
- P/E Ratio
- EVG N/A
- ABOS N/A
- Revenue Growth
- EVG N/A
- ABOS N/A
- 52 Week Low
- EVG $9.13
- ABOS $2.08
- 52 Week High
- EVG $10.86
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- EVG 40.36
- ABOS 38.88
- Support Level
- EVG $11.03
- ABOS $2.85
- Resistance Level
- EVG $11.36
- ABOS $3.36
- Average True Range (ATR)
- EVG 0.16
- ABOS 0.25
- MACD
- EVG -0.02
- ABOS -0.08
- Stochastic Oscillator
- EVG 23.96
- ABOS 3.03
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.